The CXC chemokine receptor 4 (CXCR4) in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) is crucial for vascular integrity. The atheroprotective functions of CXCR4 in vascular cells may be counteracted by atherogenic functions in other nonvascular cell types. Thus, strategies for cell-specifically augmenting CXCR4 function in vascular cells are crucial if this receptor is to be useful as a therapeutic target in treating atherosclerosis and other vascular disorders. Here, we identified miR-206-3p as a vascular-specific CXCR4 repressor and exploited a target-site blocker (CXCR4-TSB) that disrupted the interaction of miR-206-3p with CXCR4 in vitro and in vivo. In vitro, CXCR4-TSB enhanced CXCR4 expression in human and murine ECs and VSMCs to modulate cell viability, proliferation, and migration. Systemic administration of CXCR4-TSB in Apoe-deficient mice enhanced Cxcr4 expression in ECs and VSMCs in the walls of blood vessels, reduced vascular permeability and monocyte adhesion to endothelium, and attenuated the development of diet-induced atherosclerosis. CXCR4-TSB also increased CXCR4 expression in B cells, corroborating its atheroprotective role in this cell type. Analyses of human atherosclerotic plaque specimens revealed a decrease in CXCR4 and an increase in miR-206-3p expression in advanced compared with early lesions, supporting a role for the miR-206-3p–CXCR4 interaction in human disease. Disrupting the miR-206-3p–CXCR4 interaction in a cell-specific manner with target-site blockers is a potential therapeutic approach that could be used to treat atherosclerosis and other vascular diseases.

Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice / Cimen, I., Natarelli, L., Abedi Kichi, Z., Henderson, J.m., Farina, F.m., Briem, E., Aslani, M., Megens, R., Jansen, Y., Mann-Fallenbuchel, E., Gencer, S., Duchêne, J., Nazari-Jahantigh, M., Van Der Vorst, E., Enard, W., Döring, Y., Schober, A., Santovito, D., Weber, C.. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6242. - 15:720(2023). [10.1126/scitranslmed.adf3357]

Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice

Natarelli L;
2023

Abstract

The CXC chemokine receptor 4 (CXCR4) in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) is crucial for vascular integrity. The atheroprotective functions of CXCR4 in vascular cells may be counteracted by atherogenic functions in other nonvascular cell types. Thus, strategies for cell-specifically augmenting CXCR4 function in vascular cells are crucial if this receptor is to be useful as a therapeutic target in treating atherosclerosis and other vascular disorders. Here, we identified miR-206-3p as a vascular-specific CXCR4 repressor and exploited a target-site blocker (CXCR4-TSB) that disrupted the interaction of miR-206-3p with CXCR4 in vitro and in vivo. In vitro, CXCR4-TSB enhanced CXCR4 expression in human and murine ECs and VSMCs to modulate cell viability, proliferation, and migration. Systemic administration of CXCR4-TSB in Apoe-deficient mice enhanced Cxcr4 expression in ECs and VSMCs in the walls of blood vessels, reduced vascular permeability and monocyte adhesion to endothelium, and attenuated the development of diet-induced atherosclerosis. CXCR4-TSB also increased CXCR4 expression in B cells, corroborating its atheroprotective role in this cell type. Analyses of human atherosclerotic plaque specimens revealed a decrease in CXCR4 and an increase in miR-206-3p expression in advanced compared with early lesions, supporting a role for the miR-206-3p–CXCR4 interaction in human disease. Disrupting the miR-206-3p–CXCR4 interaction in a cell-specific manner with target-site blockers is a potential therapeutic approach that could be used to treat atherosclerosis and other vascular diseases.
2023
KLF4, atherosclerosis, miR-103, inflammation, endothelial cells
01 Pubblicazione su rivista::01a Articolo in rivista
Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice / Cimen, I., Natarelli, L., Abedi Kichi, Z., Henderson, J.m., Farina, F.m., Briem, E., Aslani, M., Megens, R., Jansen, Y., Mann-Fallenbuchel, E., Gencer, S., Duchêne, J., Nazari-Jahantigh, M., Van Der Vorst, E., Enard, W., Döring, Y., Schober, A., Santovito, D., Weber, C.. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6242. - 15:720(2023). [10.1126/scitranslmed.adf3357]
File allegati a questo prodotto
File Dimensione Formato  
Cimen_Targeting_2023.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.54 MB
Formato Adobe PDF
2.54 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1774135
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact